PVR and acute myeloid leukemia: Malignant cells from patients with AML with combined TET2 and TP53 mutations had profoundly elevated CD155 expression compared with other groups (Figure 9, D and E; Supplemental Figure 11, B–D; and Supplemental Table 2).